Eric Raymond
Overview
Explore the profile of Eric Raymond including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
184
Citations
7398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Xu J, Kato K, Raymond E, Hubner R, Shu Y, Pan Y, et al.
Lancet Oncol
. 2023 Apr;
24(5):483-495.
PMID: 37080222
Background: The options for first-line treatment of advanced oesophageal squamous cell carcinoma are scarce, and the outcomes remain poor. The anti-PD-1 antibody, tislelizumab, has shown antitumour activity in previously treated...
12.
Lazar V, Zhang B, Magidi S, Le Tourneau C, Raymond E, Ducreux M, et al.
Ther Adv Med Oncol
. 2023 Apr;
15:17588359231156382.
PMID: 37025260
Background: The current model of clinical drug development in oncology displays major limitations due to a high attrition rate in patient enrollment in early phase trials and a high failure...
13.
Iseas S, Prost D, Bouchereau S, Golubicki M, Robbio J, Oviedo A, et al.
Biomedicines
. 2023 Mar;
11(3).
PMID: 36979770
Anal squamous cell carcinoma (ASCC) is a rare malignancy with a rising incidence associated with human papillomavirus (HPV) infection. The locally advanced disease is associated with a 30% rate of...
14.
Evrard D, Dumont C, Gatineau M, Delord J, Fayette J, Dreyer C, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139669
Mammalian target of rapamycin (mTOR) regulates cellular functions by integrating intracellular signals and signals from the tumor microenvironment (TME). The PI3K-AKT-mTOR pathway is activated in 70% of head and neck...
15.
Lazar V, Girard N, Raymond E, Martini J, Galbraith S, Raynaud J, et al.
JCO Precis Oncol
. 2022 Sep;
6:e2200072.
PMID: 36108261
Purpose: The prognosis of patients with non-small-cell lung cancer (NSCLC), traditionally determined by anatomic histology and TNM staging, neglects the biological features of the tumor that may be important in...
16.
Harding J, Awada A, Roth G, Decaens T, Merle P, Kotecki N, et al.
Liver Cancer
. 2022 Aug;
11(3):268-277.
PMID: 35949290
Introduction: GNS561/Ezurpimtrostat is a first-in-class, orally bioavailable, small molecule that blocks cancer cell proliferation by inhibiting late-stage autophagy and dose-dependent build-up of enlarged lysosomes by interacting with the palmitoyl-protein thioesterase...
17.
Brun S, Bestion E, Raymond E, Bassissi F, Macek Jilkova Z, Mezouar S, et al.
Autophagy
. 2021 Nov;
18(3):678-694.
PMID: 34740311
Hepatocellular carcinoma is the most frequent primary liver cancer. Macroautophagy/autophagy inhibitors have been extensively studied in cancer but, to date, none has reached efficacy in clinical trials. In this study,...
18.
Hicks R, Dromain C, de Herder W, Costa F, Deroose C, Frilling A, et al.
J Neuroendocrinol
. 2021 Oct;
34(3):e13040.
PMID: 34668262
The European Neuroendocrine Tumor Society (ENETS) promotes practices and procedures that aim to improve the standard of care delivered to patients diagnosed with or suspected of having neuroendocrine neoplasia (NEN)....
19.
Belaidi L, Baba-Hamed N, Savinelli F, Raymond E
Cureus
. 2021 Aug;
13(7):e16604.
PMID: 34447643
Palbociclib (Ibrance™) has been marketed since 2015 for patients with metastatic hormone-receptor-positive breast cancer. We report here the case of a patient who presented with a posterior reversible encephalopathy syndrome...
20.
Giannelli G, Santoro A, Kelley R, Gane E, Paradis V, Cleverly A, et al.
PLoS One
. 2021 Jun;
16(6):e0253671.
PMID: 34138968
[This corrects the article DOI: 10.1371/journal.pone.0222259.].